| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
BLA Submission example | BLA | — | Subscribe to access the data. | Biologics | Nervous System | ||
BLA Submission example | BLA | — | Subscribe to access the data. | Biologics | Nervous System | ||
BLA Submission example | BLA | — | Subscribe to access the data. | Biologics | Nervous System |
Recent Updates
Recently added Catalysts
Larimar Therapeutics, Inc.$3.83
-0.17 (-4.25%)
C 54Pipeline Score Undervalued Biotech · Clinical
Market Cap
358.40 M
EPS
-2.08
P/E Ratio
-
Value Trade
5.97 M
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
25.03 M
Operating CF
-44.61 M
Total Assets
208.51 M
Total Liabilities
50.48 M
Equity
158.03 M
D/E Ratio
12,345
-10.39 %
Week
-25 %
1 Month
12.75 %
3 Month
3.29 %
6 Month
-74.44 %
5 Year
-98.56 %
All Time
Cash Data
Cash Position
200.39 M
Monthly Burn
14.87 M
Runway
11 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
1.74 M
52 Week Range
1.80 - 6.42
% held by Insiders
51.58 %
% held by Institutions
44.58 %
Enterprise Value
161.79 M
Total Shares
103.85 M
Short %
18.33 %
Float Shares
61.69 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Larimar Therapeutics, Inc.
472Total events
7Upcoming
106Tier-1 (high impact)
2014 – 2041Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2Product Launch
Subscribe to view catalyst details
Event history 2
TBD
●BLA SubmissionnomlabofuspFiledRegulatory Filing
Subscribe to view catalyst details
TBD
▲Trial InitiationnomlabofuspFiledTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-31 | nomlabofusp | BLA Filing | BLA | — | – | – | – |
2026-06-31 | nomlabofusp | BLA Filing | BLA | — | – | – | – |
2026-06-31 | nomlabofusp | BLA Filing | BLA | — | – | – | – |
Drug Pipeline Intelligence
C54
Pipeline Score $928M
Pipeline ValueUndervalued
Valuation Signal6
Drugs Scored8.6x
rNPV / MCap Top 83%
Micro Cap (rank 156 of 913)
Percentile RankLarimar Therapeutics, Inc. carries a moderate pipeline score (54/100), with $4.1B risk-adjusted pipeline value, led by ZGN-1061 in Type 2 Diabetes Mellitus (Phase 2), across $126B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZGN-1061 Small molecule | Type 2 Diabetes Mellitus | Phase 2 | NCT03254368 | 23% | $2.5B | COMPLETED | 188 | - | - | Feb 22, 2019 | - | May 24, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
nomlabofusp BreakthroughFast TrackOrphan+1 | Friedreich's ataxia | — | 2025-09-29 | consistent improvements in clinical outcomes; increased frataxin levels; 25 mg and 50 mg data; achieving tissue FXN levels equivalent to more than 50% of those found in healthy volunteers Read More | Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia Read More | |
nomlabofusp BreakthroughFast TrackOrphan+1 | Friedreich's ataxia | — | 2025-09-29 | consistent improvements in clinical outcomes; increased frataxin levels; 25 mg and 50 mg data; achieving tissue FXN levels equivalent to more than 50% of those found in healthy volunteers Read More | Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia Read More | |
nomlabofusp BreakthroughFast TrackOrphan+1 | Friedreich's ataxia | — | 2025-09-29 | consistent improvements in clinical outcomes; increased frataxin levels; 25 mg and 50 mg data; achieving tissue FXN levels equivalent to more than 50% of those found in healthy volunteers Read More | Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LRMR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LRMR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LRMR▼ -12.6%on this news
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
Larimar Therapeutics has submitted the first module of its rolling Biologics License Application (BLA) for nomlabofusp, aimed at treating Friedreich's ataxia. Positive results from a long-term open label study showed significant improvements in skin FXN levels and clinical outcomes. The FDA has indicated that the existing data supports the BLA submission, with further modules expected by the end of 2026.
Read more →LRMR▼ -12.6%on this newsshared move
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
Larimar Therapeutics announced an investor event scheduled for June 29, 2026, to discuss updates on its nomlabofusp program for Friedreich's ataxia. The event will include a regulatory update and data from ongoing studies. Larimar aims to develop treatments for complex rare diseases, with nomlabofusp as a key candidate.
Read more →LRMR▼ -5.1%on this news· ran to -19% by day 3
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
Larimar Therapeutics reported its Q1 2026 financial results, highlighting plans for a rolling BLA submission for nomlabofusp, aimed at treating Friedreich's ataxia. The company has received Breakthrough Therapy Designation from the FDA and expects to report topline data from an open-label study in Q2 2026. With $200.4 million in cash, Larimar is positioned to advance its clinical programs.
Read more →LRMR▼ -6.5%on this news
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
Larimar Therapeutics has published findings supporting the use of skin as a surrogate for measuring frataxin levels in patients with Friedreich's ataxia. The study indicates that treatment with nomlabofusp increases frataxin levels in peripheral tissues, correlating with levels in critical organs. These findings bolster Larimar's plans for accelerated approval from the FDA and a Biologics License Application submission scheduled for June 2026.
Read more →LRMRLarimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results • Breakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA's review of
Larimar Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting the receipt of Breakthrough Therapy Designation from the FDA for nomlabofusp, aimed at treating Friedreich's ataxia. The company successfully raised $115 million in a public offering, extending its cash runway into the second quarter of 2027. Plans are in place to initiate a global Phase 3 confirmatory study in mid-2026 and submit a Biologics License Application seeking accelerated approval in June 2026. However, the company reported a net loss for 2025 of $165.7 million, reflecting significant increases in research and development costs.
Read more →LRMR▲ +9%on this news
pro March 2026 Larimar Therapeutics Corporate Deck Forward-Looking Statements This presentation contains forward-looking statements that are based on Larimar's management's beliefs and assumptions and on information curr
Larimar Therapeutics has shared an update on its promising drug candidate nomlabofusp, which has received FDA Breakthrough Therapy Designation for Friedreich's Ataxia (FA). The company plans to submit a Biologics License Application (BLA) in June 2026, following positive early clinical results that show significant improvements in FXN levels. However, various risks remain, including potential delays and uncertainties in clinical trial outcomes.
Read more →LRMRLarimar Therapeutics to Participate in Upcoming Investor Conferences in March 2026
Larimar Therapeutics, a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences in March 2026. The conferences will take place in Miami Beach, FL, where the management team will present and hold 1x1 meetings with investors. The company aims to showcase its lead compound, nomlabofusp, which targets Friedreich's ataxia.
Read more →LRMR▼ -7.2%on this news
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
Larimar Therapeutics has announced a proposed underwritten public offering of $75 million in common stock and pre-funded warrants. The company plans to utilize the proceeds for the development of its lead compound, nomlabofusp, and for general corporate purposes. The offering is contingent on market conditions and may not be finalized as planned.
Read more →LRMR▼ -7.2%on this news
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
Larimar Therapeutics has announced the pricing of its upsized public offering, raising $100 million by selling 20 million shares at $5.00 each. The offering is set to close around February 27, 2026, and the proceeds will be used for the development of nomlabofusp and general corporate purposes. The company has granted underwriters a 30-day option for additional shares.
Read more →LRMR▲ +31.3%on this news· ran to +112% by day 1shared move
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
Larimar Therapeutics has received Breakthrough Therapy Designation from the FDA for nomlabofusp, a treatment for Friedreich's ataxia. The designation highlights the drug's potential to significantly improve clinical outcomes based on preliminary data. The company plans to submit a Biologics License Application (BLA) by June 2026, aiming for accelerated approval. FDA feedback indicates alignment on clinical endpoints and study design.
Read more →LRMRpro January 2026 Larimar Therapeutics Corporate Deck Forward-Looking Statements This presentation contains forward-looking statements that are based on Larimar's management's beliefs and assumptions and on information cu
Larimar Therapeutics presented its corporate deck highlighting forward-looking statements regarding the development of nomlabofusp, a potential treatment for Friedreich's ataxia. The company aims to register this first-in-class mitochondrial protein replacement therapy, targeting systemic frataxin deficiency. Strong preliminary studies support the efficacy of nomlabofusp, and regulatory pathways appear promising. However, the management acknowledges risks and uncertainties associated with the drug's development timeline and regulatory approvals.
Read more →LRMRLarimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Larimar Therapeutics, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco. The presentation by the management team will take place on January 14 from 9:00 to 9:40 AM PST, followed by a 30-day replay available on their website. The company is focused on developing treatments for complex rare diseases, particularly its lead compound for Friedreich's ataxia.
Read more →LRMRpro November 2025 Larimar Therapeutics Corporate Deck Forward-Looking Statements This presentation contains forward-looking statements that are based on Larimar's management's beliefs and assumptions and on information c
Larimar Therapeutics has presented forward-looking statements regarding its drug nomlabofusp for Friedreich's Ataxia (FA), suggesting strong potential as a disease-modifying therapy. Initial open-label studies indicated significant increases in skin frataxin levels and improvements across clinical metrics in study participants. While results are promising, there are concerns about adverse events such as anaphylaxis and uncertainty in FDA interactions affecting future developments. Larimar targets a Biologics License Application submission by Q2 2026, contingent on continued positive results and further clinical data.
Read more →LRMR▼ -15.3%on this newsshared move
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
Larimar Therapeutics reported its third quarter 2025 financial results, highlighting positive long-term data from its open label study of nomlabofusp for Friedreich's ataxia. The study showed significant improvements in clinical outcomes and skin FXN levels. However, the company also noted an increase in net losses and research expenses, along with some cases of anaphylaxis among participants. Larimar aims to submit a Biologics License Application in the second quarter of 2026.
Read more →LRMRpro October 2025 Larimar Therapeutics Corporate Deck Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “
Larimar Therapeutics has provided an update on its development of nomlabofusp, with initial results indicating its potential as a disease-modifying therapy for Friedreich's Ataxia (FA). A corporate deck presented forward-looking statements regarding the drug's regulatory path, including plans for a Biologics License Application (BLA) in Q2 2026. Despite encouraging data showing significant improvements in skin FXN levels among trial participants, the company faced challenges, including adverse events like anaphylaxis, which led to modifications of the clinical regimen. Overall, Larimar remains optimistic about nomlabofusp's potential and its alignment with FDA guidelines for accelerated approval.
Read more →LRMR▼ -33.7%on this newsshared move
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
Larimar Therapeutics announced positive results from its long-term open-label study of nomlabofusp for Friedreich's ataxia, showing consistent improvements in clinical outcomes and increased frataxin levels. The treatment was well-tolerated among participants, with ongoing updates provided to the FDA. However, allergic reactions, including anaphylaxis, remain a concern.
Read more →LRMR▼ -33.7%on this newsshared move
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
Larimar Therapeutics has announced a conference call scheduled for September 29, 2025, to discuss updates on its nomlabofusp clinical development program for Friedreich's ataxia. The call will include data from an ongoing long-term open label study. Participants can join via phone or webcast, with an archived version available post-event.
Read more →LRMR▲ +14.5%on this news
Larimar Therapeutics Reports Second Quarter 2025 Financial Results • Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025 •
Larimar Therapeutics reported its financial results for the second quarter of 2025, highlighting a net loss of $26.2 million. The company continues to advance its nomlabofusp program with initial data from the 50 mg open label study and adolescent PK run-in expected in September 2025. Additionally, plans to submit a Biologics License Application seeking accelerated approval in Q2 2026 are underway. The company also announced a strengthened balance sheet following a public offering that extended its cash runway into late 2026.
Read more →LRMRLarimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Larimar Therapeutics has successfully closed an underwritten public offering of 21,562,500 shares at $3.20 each, raising approximately $69 million. The funds will be allocated to the development of their lead compound, nomlabofusp, and other pipeline projects. The offering's success reflects strong market confidence in Larimar's future prospects.
Read more →LRMRLarimar Therapeutics Announces Pricing of Underwritten Public Offering
Larimar Therapeutics has announced the pricing of its public offering, selling 18.75 million shares at $3.20 each, aiming to raise approximately $60 million. The offering, which is set to close around July 31, 2025, will support the development of its lead candidate, nomlabofusp, and other pipeline projects. The company has granted underwriters a 30-day option for additional shares.
Read more →LRMRLarimar Therapeutics Announces Proposed Underwritten Public Offering
Larimar Therapeutics has announced a proposed underwritten public offering of its common stock and pre-funded warrants. The company aims to use the proceeds for the development of its lead compound, nomlabofusp, and other pipeline candidates. The offering is subject to market conditions and includes an option for underwriters to purchase additional shares.
Read more →LRMRLarimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia
Larimar Therapeutics has published two peer-reviewed articles detailing nonclinical data on nomlabofusp, a potential treatment for Friedreich's ataxia. The data supports its mechanism of action and pharmacology, contributing to the FDA's consideration of skin FXN concentrations as a surrogate endpoint for accelerated approval. A Biologics License Application is planned for Q2 2026.
Read more →LRMR▼ -6.6%on this news· ran to +19% by day 3
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program
Larimar Therapeutics announced FDA recommendations on safety data for its Biologics License Application (BLA) for nomlabofusp, aimed at treating Friedreich's Ataxia. The company plans to submit the BLA for accelerated approval in Q2 2026. Enrollment in the open label extension study is expanding to include more patients, and promising data is expected in September 2025.
Read more →LRMR▼ -6.6%on this news· ran to +19% by day 3shared move
This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All state
Larimar Therapeutics, Inc. presented forward-looking statements regarding the development of nomlabofusp (CTI-1601), a protein replacement therapy for Friedreich's ataxia (FA). The company anticipates submitting a Biologics License Application (BLA) seeking accelerated approval by Q2 2026, backed by positive data from ongoing studies. Larimar reported clear expectations from the FDA regarding the BLA submission process, alongside updates on safety and tolerability data from preliminary trials. However, there are noted risks related to clinical trial uncertainties and regulatory approval challenges.
Read more →LRMR▼ -5.5%on this news· ran to +19% by day 3shared move
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
Larimar Therapeutics announced a regulatory update call to discuss the nomlabofusp clinical development program aimed at treating Friedreich's Ataxia. The call is scheduled for June 23, 2025, and will be accessible via phone and webcast. This initiative reflects Larimar's commitment to transparency regarding its development activities in the rare disease sector. The company aims to provide insights into the progress and regulatory strategies related to nomlabofusp, its leading product candidate.
Read more →LRMR▼ -9.4%on this news· ran to -29% by day 1
pro May 2025 Larimar Therapeutics Corporate Deck This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on informa
Larimar Therapeutics is making advancements in the development of nomlabofusp (CTI-1601), a protein replacement therapy for patients with Friedreich's ataxia. The FDA has indicated openness to considering skin FXN concentrations as a surrogate endpoint for accelerated approval. Positive initial data from ongoing studies support the potential effectiveness of the treatment. The company plans to initiate a global Phase 3 study by mid-2025, with a Biologics License Application targeted for submission by the end of 2025, leveraging their strong financial position.
Read more →LRMR▲ +10.9%on this newsshared move
Larimar Therapeutics Reports First Quarter 2025 Financial Results • FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoi
Larimar Therapeutics reported its first quarter 2025 financial results alongside updates on its nomlabofusp clinical development. The FDA indicated willingness to consider skin FXN concentration as a potential surrogate endpoint for accelerated approval. Financially, the company has a robust balance sheet with $157.5 million in cash but reported a larger net loss compared to the previous year. A global Phase 3 study is anticipated to start in mid-2025, with significant data readouts expected later this year.
Read more →LRMR▼ -10.2%on this news
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results • FDA stated in written correspondence for a START pilot program meeting that it is open
Larimar Therapeutics has provided an update on the development of nomlabofusp, reporting positive engagement with the FDA regarding the use of skin FXN concentrations as a potential surrogate endpoint for accelerated approval. The company plans to submit a Biologics License Application (BLA) by the end of 2025, with regulatory discussions ongoing to assess safety data. Financially, Larimar reported a net loss of $28.8 million for Q4 2024, alongside significant R&D expenses attributable to increased manufacturing costs. The company remains optimistic about launching a global Phase 3 study in mid-2025 and potential commercial products in the future.
Read more →LRMR▼ -12.5%on this news
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Larimar Therapeutics, Inc. (Nasdaq: LRMR) will present at the Leerink Partners Global Healthcare Conference in Miami Beach from March 10-12, 2025. Members of the management team will also engage in one-on-one investor meetings during the event. The company's lead compound, nomlabofusp, is under development for treating Friedreich's ataxia. Further details about the presentation and replay capabilities were shared on their website.
Read more →LRMRLarimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
Larimar Therapeutics has announced the commencement of dosing adolescents aged 12-17 in their pediatric pharmacokinetic run-in study targeting Friedreich’s ataxia. This marks an important step in assessing the safety and pharmacokinetics of nomlabofusp in younger patients. The study aims to enroll adolescents and will soon include a cohort of children aged 2-11 in the first half of 2025. Long-term data from both adult and adolescent participants is anticipated by mid-2025, indicating a forward-looking approach to treatment efficacy.
Read more →LRMRpro January 2025 Larimar Therapeutics Corporate Deck Exhibit 99.1
Larimar Therapeutics is advancing its clinical candidate nomlabofusp (CTI-1601), aimed at addressing frataxin deficiency in Friedreich's Ataxia (FA). The compound has shown dose-dependent increases in frataxin levels in previous studies, and discussions are ongoing with the FDA regarding an accelerated approval pathway. The company plans to submit a Biologics License Application (BLA) in the second half of 2025. However, challenges remain, including uncertainties regarding clinical trial results and regulatory requirements.
Read more →LRMR▼ -21.7%on this news
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia • Daily subcutaneous injections of 25 mg nomlabo
Larimar Therapeutics reported positive initial data from its ongoing long-term open-label extension study of nomlabofusp for Friedreich's ataxia. The study included 14 participants receiving daily subcutaneous injections, which increased tissue frataxin levels significantly after 90 days. Preliminary trends indicate potential clinical improvements, and the company plans to expand dosing to 50 mg in current participants. Additionally, a pediatric study is in the works, with a biologics license application targeted for late 2025. The financial health of the company remains strong, facilitating the continuation of their clinical studies.
Read more →LRMR▼ -7.9%on this news
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
Larimar Therapeutics presented promising data on nomlabofusp at the ICAR 2024 conference. The findings indicate that daily administration could achieve significant FXN levels in patients with Friedreich's ataxia, aligning with levels in asymptomatic carriers. The company's ongoing studies will expand participant demographics, and they intend to submit a Biologics License Application by the second half of 2025. Further data collection and analysis are expected in the coming months to enhance understanding and development of the therapy.
Read more →LRMR▲ +8.7%on this news
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results • Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as av
Larimar Therapeutics announced its third quarter 2024 financial results, reporting a net loss of $15.5 million. The company is moving forward with its nomlabofusp program, aimed to treat Friedreich's ataxia, with upcoming data releases expected in mid-December. A PK run-in study for adolescents is planned for the end of 2024, and global confirmatory studies are targeted for mid-2025, leading to a Biologics License Application submission in the second half of 2025. The company maintains a strong cash position, providing a runway into 2026.
Read more →LRMRLarimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
Larimar Therapeutics announced that they will present data from their nomlabofusp Phase 1 and Phase 2 studies at the upcoming International Congress for Ataxia Research in London. The presentations will include an oral session and cover topics related to tissue frataxin levels and the effects of nomlabofusp on patients with Friedreich's ataxia. Nomlabofusp has received several important designations from regulatory agencies, emphasizing its potential as a treatment for this condition. The company is committed to developing novel therapies for complex rare diseases.
Read more →LRMRLarimar Therapeutics to Participate in Upcoming Investor Conferences
Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced its management team will participate in upcoming investor meetings at two significant conferences: the Wells Fargo Healthcare Conference in Boston and the H.C. Wainwright Global Investment Conference in New York. These events, scheduled for early September 2024, provide an opportunity for the company to engage with investors and discuss its developments in rare disease treatments. Larimar's lead compound, nomlabofusp, aims to treat Friedreich's ataxia, underscoring the company's focus on complex rare diseases.
Read more →LRMR▼ -6.5%on this news
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results • Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024 • Selected by
Larimar Therapeutics reported its second quarter 2024 financial results, highlighting significant progress in its open label extension study for nomlabofusp, with all seven sites now active. The company was selected by the FDA for the START pilot program to aid in clinical trials for rare disease therapeutics. With a strong cash position of $226.1 million, Larimar plans to initiate a pharmacokinetic run-in study for adolescents by the end of 2024 and a global confirmatory study by mid-2025, targeting a Biologics License Application submission in the latter half of 2025. However, the company also reported increased net losses and operational costs during this period.
Read more →LRMRLarimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia • START is a new milestone-driven program designed to accelerate development of novel therapies int
Larimar Therapeutics has announced that its experimental therapy, nomlabofusp, has been selected by the FDA to participate in the START pilot program, aimed at accelerating the development of treatments for rare diseases. The choice reflects the therapy's potential benefits for patients suffering from Friedreich's ataxia, a neurodegenerative condition. This pilot program will enhance communications between Larimar and the FDA, which could expedite clinical studies and future regulatory approvals. The company is targeting a Biologics License Application (BLA) submission in the second half of 2025.
Read more →LRMRLarimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia • Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 do
Larimar Therapeutics has announced that the FDA has lifted a partial clinical hold on its nomlabofusp program for Friedreich's Ataxia after reviewing Phase 2 study data. The company plans to escalate its dosing from 25 mg to 50 mg following additional analysis of pharmacodynamics. The ongoing open label extension study aims to evaluate the long-term safety and tolerability of nomlabofusp, with interim data expected in Q4 2024 and a biologics license application targeted for the second half of 2025. Nomlabofusp has shown encouraging results concerning frataxin levels, indicating its potential as a treatment for this rare disease.
Read more →LRMRLarimar Therapeutics Reports First Quarter 2024 Operating and Financial Results • First patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp; interim data on track for Q4 2024 &
Larimar Therapeutics reported strong first-quarter results for 2024, including the dosing of the first patient in an open label extension study of nomlabofusp, aimed at treating Friedreich's ataxia. Positive data from a Phase 2 study indicate the drug is well-tolerated and leads to increased frataxin levels. The company secured $161.8 million in financing, which supports its operations and extends its cash runway into 2026. Furthermore, progress is being made towards a Biologics License Application submission targeted for the second half of 2025.
Read more →LRMR▼ -6.5%on this news
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development • Positive top-line data from Phase 2 dose exploration study of nomlabo
Larimar Therapeutics reported significant advancements in their nomlabofusp program, highlighted by positive top-line results from a Phase 2 study demonstrating its efficacy in increasing tissue frataxin levels. The company initiated discussions with the FDA for potential accelerated approval and is targeting a Biologics License Application submission for the second half of 2025. Additionally, a recent financing round raised $161.6 million, supporting ongoing development and operational activities.
Read more →LRMR▼ -15.4%on this newsshared move
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia • Study will inform on long-term safety profile and tissu
Larimar Therapeutics has initiated dosing of the first patient in a long-term open label extension study for their treatment nomlabofusp, targeting patients with Friedreich's ataxia. The study is designed to evaluate the long-term safety and tissue frataxin levels, using a 25 mg daily subcutaneous injection. Initial results are anticipated in Q4 2024, and the company plans to submit a Biologics License Application for accelerated approval by the second half of 2025 based on the findings of this study.
Read more →LRMRLarimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Larimar Therapeutics, a clinical-stage biotechnology company, announced that its management team will present at the Leerink Partners Global Biopharma Conference in Miami Beach, FL, from March 11 to 13, 2024. The presentation will include participation in 1x1 investor meetings, aimed at increasing engagement with investors. The company continues to focus on treatments for complex rare diseases, such as Friedreich's ataxia, with its lead compound, nomlabofusp. A webcast of the presentation will be available for replay on Larimar's website for 30 days post-event.
Read more →LRMR▲ +36.8%on this news· ran to +52% by day 1shared move
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
Larimar Therapeutics, Inc. has announced the pricing of its public offering of 17,162,472 shares of common stock, priced at $8.74 per share. The offering is expected to generate approximately $150 million in gross proceeds, which will be utilized for the development of their lead candidate nomlabofusp and other products. The closing of the offering is anticipated on or about February 16, 2024, pending customary conditions. The company has also provided underwriters with an option to purchase additional shares, enhancing potential capital raised.
Read more →LRMRLarimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia • Nomlabofusp was generally well tolerated f
Larimar Therapeutics has announced positive results from its Phase 2 dose exploration study of nomlabofusp in patients with Friedreich's ataxia. The treatment demonstrated dose-dependent increases in frataxin levels and was well tolerated, with no serious adverse events reported. The company is also initiating an Open Label Extension study and has begun discussions with the FDA regarding a potential Biologics License Application targeting the second half of 2025. Initial safety and efficacy data from the Open Label study is expected by Q4 2024.
Read more →LRMR▲ +7.1%on this news· ran to +38% by day 3
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results • Completed full enrollment and dosing of the 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial; based on blind
Larimar Therapeutics reported its third quarter results, highlighting the successful completion of the 50 mg cohort enrollment and dosing in their Phase 2 trial for Friedreich's ataxia. There were no reported serious adverse events during the trial, and top-line data is expected in Q1 2024. The company maintains a solid cash position of $95.6 million, projected to sustain operations into Q1 2025. Plans for an open label extension trial are also on schedule, with interim data anticipated in Q4 2024.
Read more →LRMRLarimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference
Larimar Therapeutics, Inc. will present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference in New York on November 7, 2023. The company's management team will participate in a fireside chat and one-on-one investor meetings. The event will also be accessible via webcast, with a replay available for 30 days on the company’s website. Larimar is focused on developing treatments for complex rare diseases, including Friedreich's ataxia.
Read more →LRMR▼ -5.8%on this news
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
Larimar Therapeutics has appointed Dr. Jeffery W. Sherman to its Board of Directors, effective immediately. Dr. Sherman, who is currently the Chief Medical Officer at Horizon Therapeutics, has extensive experience in regulatory and clinical strategy, particularly within rare diseases such as Friedreich's ataxia. His addition to the board is expected to enhance Larimar's strategic approach as it advances the development of its lead therapy, CTI-1601, aimed at treating rare diseases. The company anticipates leveraging Dr. Sherman’s insights and relationships in the biotech industry to further its clinical development efforts.
Read more →LRMRLarimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference
Larimar Therapeutics, a clinical-stage biotechnology company, will participate in the Citi 18th Annual BioPharma Conference in Boston from September 5-7, 2023. Company management will engage in a panel discussion focused on rare neurological diseases on September 6. Larimar is working on developing treatments for complex rare diseases, particularly through its lead compound, CTI-1601, for Friedreich's ataxia.
Read more →LRMRLarimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results • Initiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 2
Larimar Therapeutics has reported its second quarter 2023 financial results, highlighting significant advancements in its clinical trials for CTI-1601, focused on Friedreich's ataxia (FA). The company received FDA clearance to initiate a 50 mg cohort in its Phase 2 trial and to proceed with an open-label extension study, following positive results from a previous 25 mg cohort. With a strong cash position, Larimar aims to report key data in 2024 to inform future study designs. Despite a net loss of $8.4 million for the quarter, the company remains optimistic about its development pipeline.
Read more →LRMR▲ +7.7%on this news· ran to +27% by day 3
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial • Top-line safety, pharmacokinetic, and pharmacodyn
Larimar Therapeutics has received FDA clearance to escalate its Phase 2 trial of CTI-1601 for Friedreich's ataxia to a 50 mg cohort. Additionally, the company will initiate an open label extension trial starting Q1 2024 with a 25 mg daily dosing. Preliminary data from prior cohorts suggest that CTI-1601 is generally well tolerated and has shown promise in increasing frataxin levels among participants. Further results from the Phase 2 trial are anticipated in the first half of 2024, which will aid in assessing CTI-1601's safety and effectiveness.
Read more →LRMRLarimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
Larimar Therapeutics has appointed Dr. Rusty Clayton as its new Chief Medical Officer, taking over from retiring CMO Nancy M. Ruiz. Dr. Clayton has advised Larimar for five years and was closely involved with FDA meetings. He aims to advance the development of CTI-1601, targeting Friedreich's ataxia. To incentivize his role, the company has granted him stock options to enhance leadership stability as they progress towards clinical trials.
Read more →LRMRLarimar Therapeutics Set to Join Russell 3000 Index
Larimar Therapeutics, Inc. is set to join the Russell 3000 Index effective June 26, 2023. This addition will provide increased visibility and potential investment opportunities as the index is widely recognized by institutional investors. Larimar, focused on developing treatments for complex rare diseases, could benefit from this inclusion which reflects its market capitalization. The company's lead compound aims to address Friedreich's ataxia, showcasing its commitment to innovative therapies.
Read more →LRMRJune 2023 Larimar Therapeutics Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “
Larimar Therapeutics held a corporate presentation in June 2023, discussing forward-looking statements regarding their lead candidate, CTI-1601, for Friedreich's Ataxia. The presentation outlined the company’s expectations for overcoming a current partial clinical hold imposed by the FDA and the development progress of CTI-1601, a recombinant fusion protein aimed at increasing frataxin levels. Despite positive preliminary results, various risks, including regulatory hurdles and the unpredictability of clinical outcomes, were highlighted. The company also emphasized their solid financial position, with funding ensuring operations into the latter half of 2024.
Read more →LRMR▼ -29.1%on this news
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial's 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich's Ataxia and First Quarter 2023 Financial Results • Safety
Larimar Therapeutics announced preliminary data from a Phase 2 trial of CTI-1601, indicating significant increases in frataxin levels in patients with Friedreich's ataxia. The trial's 25 mg cohort showed that the treatment was generally well tolerated, with only one severe allergic reaction reported. Larimar plans to submit the findings to the FDA and discuss advancing to a 50 mg cohort later this quarter. Financially, the company reported a net loss of $6.5 million for Q1 2023, a decrease compared to the previous year.
Read more →LRMRLarimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days
Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced its participation in the Guggenheim Genomic Medicines and Rare Disease Days from April 3-4, 2023. Company management will engage in a virtual fireside chat and one-on-one investor meetings during the event. This participation highlights Larimar's focus on developing treatments for complex rare diseases, including its lead compound CTI-1601 for Friedreich's ataxia. A live webcast of the discussion will be available for interested parties.
Read more →LRMRLarimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results First cohort of Larimar s Phase 2 dose exploration trial of CTI-1601 in participants with Friedreich s ataxia (FA) is fully e
Larimar Therapeutics has reported its financial results for the fourth quarter and full year of 2022, highlighting a net loss of $35.4 million. The company's main focus remains on developing CTI-1601 to treat Friedreich's ataxia, with the first cohort of its Phase 2 trial fully enrolled. In addition, Larimar strengthened its leadership team and financial position through recent financing efforts. Upcoming updates regarding the trial's next steps are expected in the second quarter of 2023.
Read more →LRMR▲ +6.5%on this news· ran to +21% by day 3
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer Biologics expert and long-time veteran of Johnson & Johnson will be responsible for the strategic development of Larimar s clinical and R&D prog
Larimar Therapeutics has appointed Dr. Gopi Shankar as the new Chief Development Officer. Dr. Shankar will oversee the strategic development of the company's clinical and R&D programs, particularly focusing on the CTI-1601 program aimed at treating Friedreich's ataxia. With over 20 years of experience in biologics development at Johnson & Johnson, he is expected to enhance the company's growth and innovation strategies. The move aligns with Larimar's goal of leveraging its platform technology to address complex rare diseases.
Read more →LRMR▲ +5.2%on this news
January 2023 Larimar Therapeutics Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( 
Larimar Therapeutics presented forward-looking statements concerning its pipeline, specifically focusing on CTI-1601, a treatment for Friedreich's ataxia. They reported completion of Phase 1 trials with positive data regarding frataxin levels, and an ongoing Phase 2 study aiming to explore dosing and safety. However, the study is under a partial clinical hold pending FDA review, which adds a layer of uncertainty to its development timeline. The company highlighted a robust financial position that supports its research endeavors into 2024.
Read more →LRMRLarimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
BALA CYNWYD, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will present and participate in 1x
Read more →LRMRLarimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results - First cohort of Larimar's Phase 2 dose exploration trial of CTI-1601 in Friedreich's ataxia patients is ongoing and proceeding in line wit
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results -First cohort of Larimar's Phase 2 dose exploration trial of CTI-1601 in Friedreich's ataxia patients is ongoing and proceeding in line with the Company's planned timeline -Larimar expects to provid
Read more →LRMRLarimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day
BALA CYNWYD, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a virtual fire
Read more →LRMRLarimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601
Patent extends Larimar’s intellectual property protection for CTI-1601 into at least July 2040 BALA CYNWYD, Pa., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for c
Read more →LRMROctober 2022 Larimar Therapeutics Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( 
October 2022 Larimar Therapeutics Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( Company ) and on information currently available to management.
Read more →LRMRLarimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research
BALA CYNWYD, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program eval
Read more →LRMR▼ -5%on this news
Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares
BALA CYNWYD, Pa., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced
Read more →LRMR▲ +15.6%on this newsshared move
Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich s Ataxia Patients - Initiation of the Phase 2 trial is expected in Q4 2022, with top
Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich s Ataxia Patients - Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 - Company management host
Read more →LRMR▲ +15.6%on this newsshared move
Larimar Therapeutics Announces $70 Million Underwritten Offering
BALA CYNWYD, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of an underwritten offering
Read more →LRMRLarimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results - Larimar plans to
Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results -Larimar plans to submit a complete response to CTI-1601's clinical hold in th
Read more →LRMRLarimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders
BALA CYNWYD, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that preclinical studies evaluating CTI-1601’s effects on
Read more →LRMRLarimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts
BALA CYNWYD, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that biomarker studies that have identified genes that are
Read more →LRMRLarimar Therapeutics Announces Upcoming Scientific Conference Presentations
BALA CYNWYD, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced upcoming presentations at the United Mitochondrial Disease
Read more →LRMRLarimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress
BALA CYNWYD, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evalu
Read more →LRMR▼ -7.9%on this news
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results -CTI-1601 Type C Meeting to discuss clinical hold has been granted by the U.S. Food and Drug Administration and is scheduled for early in th
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results -CTI-1601 Type C Meeting to discuss clinical hold has been granted by the U.S. Food and Drug Administration and is scheduled for early in the third quarter of 2022 - Cash at March 31, 2022 of $62.6
Read more →LRMRLarimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results Bala Cynwyd, PA
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results Bala Cynwyd, PA, March 25, 2022 Larimar Therapeutics, Inc. ( Larimar ) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disease
Read more →LRMR▲ +12.1%on this news
Larimar Therapeutics Corporate Presentation February 2022 1 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (th
Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the "Company") and on information currently available to management. All statements contained in this presentation other
Read more →LRMRLarimar Therapeutics Provides Update on CTI-1601 Clinical Program Bala Cynwyd, PA
Larimar Therapeutics Provides Update on CTI-1601 Clinical Program Bala Cynwyd, PA, February 14, 2022 Larimar Therapeutics, Inc. ( Larimar ) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it
Read more →LRMRLarimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
BALA CYNWYD, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in virtual 1x1 in
Read more →LRMRLarimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference
BALA CYNWYD, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor m
Read more →LRMR▼ -8.7%on this newsshared move
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results Bala Cynwyd, PA
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results Bala Cynwyd, PA, November 12, 2021 Larimar Therapeutics, Inc. ( Larimar ) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today rep
Read more →LRMR▼ -7.5%on this news
Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event
BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor
Read more →LRMR▲ +5.8%on this news
Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
BALA CYNWYD, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive
Read more →LRMRLarimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress
BALA CYNWYD, Pa., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that David Bettoun, PhD, Vice President Discovery & Non-Cl
Read more →LRMR▲ +17.8%on this news
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results - Reported positive proof-of-concept and dose response data from Phase 1 program evaluating CTI-1601 in patients with Friedreich s ataxia (
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results - Reported positive proof-of-concept and dose response data from Phase 1 program evaluating CTI-1601 in patients with Friedreich s ataxia (FA) Subcutaneous injections of CTI-1601 at doses of 50 mg
Read more →LRMRLarimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021
BALA CYNWYD, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive
Read more →LRMRLarimar Therapeutics Corporate Presentation July 2021 1 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the "C
1Exhibit 99.1 Larimar Therapeutics Corporate Presentation July 2021 1 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the "Company") and on information currently availa
Read more →LRMRLarimar Therapeutics Corporate Presentation June 2021 1 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the "C
1Exhibit 99.1 Larimar Therapeutics Corporate Presentation June 2021 1 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the "Company") and on information currently availa
Read more →LRMRLarimar Therapeutics to Present at the JMP Securities Life Sciences Conference
BALA CYNWYD, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive
Read more →LRMRLarimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing Bala Cynwyd, PA
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing Bala Cynwyd, PA, May 25, 2021 Larimar Therapeutics, Inc. ( Larimar ) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatm
Read more →LRMRLarimar Therapeutics Announces $95 Million Private Placement Financing
BALA CYNWYD, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s ataxia (FA) and other complex rare diseases, today announced that it has executed a s
Read more →LRMRLarimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich s Ataxia Bala Cynwyd, PA
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich s Ataxia Bala Cynwyd, PA, May 20, 2021 Larimar Therapeutics, Inc. ( Larimar ) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing t
Read more →LRMRForward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the "Company") and on information currently available to manag
May 2021 Larimar Therapeutics Corporate Presentation Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the "Company") and on information currently available
Read more →LRMRForward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the "Company) and on information currently available to manage
May 11, 2021 Larimar Therapeutics Phase 1 Topline Data Conference Call Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the "Company) and on information cu
Read more →LRMRLarimar Therapeutics Reports First Quarter 2021 Operating and Financial Results - Topline data from placebo-controlled Phase 1 program in Friedreich s ataxia patients to be announced tomorrow
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results - Topline data from placebo-controlled Phase 1 program in Friedreich s ataxia patients to be announced tomorrow, May 11, 2021- Management to discuss during webcast and conference call at 8 a.m. ET
Read more →LRMRLarimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia
Data demonstrate proof-of-concept by showing that daily subcutaneous injections of CTI-1601 for up to 13 days resulted in dose-dependent increases in frataxin levels from baseline compared to placebo in all evaluated tissues Data show that frataxin levels achieved in peripheral
Read more →LRMRLarimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results - Reported preliminary Phase 1 findings from a Single Ascending Dose (SAD) trial that suggest single subcutaneous injections
Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results - Reported preliminary Phase 1 findings from a Single Ascending Dose (SAD) trial that suggest single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg in Fr
Read more →LRMRLarimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference
BALA CYNWYD, Pa., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive
Read more →LRMRLarimar Therapeutics Added to NASDAQ Biotechnology Index
BALA CYNWYD, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has been selected for addition to the NASDAQ Biote
Read more →LRMRForward Looking Statements This presentation contains forward-looking statements that are based on the Company's beliefs and assumptions and on information currently available to management. All statements contained in t
December 2020 Larimar Therapeutics Corporate Presentation Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements that are based on the Company's beliefs and assumptions and on information currently available to management. All statements
Read more →LRMRLarimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update
- Preliminary data suggest that single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg - Company remains on track to report topline data from placebo-controlled single and multiple ascending dose clinical trials in Q2 2021 BALA CYNWYD, Pa., Dec. 08
Read more →LRMRLarimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results Phase 1 trials evaluating CTI-1601 as a treatment for Friedreich s ataxia on track for topline data in 1H 2021 Received orphan drug designat
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results Phase 1 trials evaluating CTI-1601 as a treatment for Friedreich s ataxia on track for topline Received orphan drug designation for CTI-1601 from the European Commission Cash, cash equivalents, and
Read more →LRMRLarimar Therapeutics Announces Formation of Scientific Advisory Board
BALA CYNWYD, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the formation of its Scientific Advisory Board (SAB). Larimar’s SAB is
Read more →LRMRLarimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
BALA CYNWYD, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, wil
Read more →LRMRLarimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
BALA CYNWYD, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, wil
Read more →LRMRLarimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results Merger between Chondrial Therapeutics and Zafgen completed and company began operating as Larimar Therapeutics Phase 1 clinical trial of CT
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results Bala Cynwyd, PA August 11, 2020 Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its secon
Read more →LRMRLarimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
BALA CYNWYD, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will
Read more →LRMRLarimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia
BALA CYNWYD, Pa., July 28, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal
Read more →LRMRLarimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia
BALA CYNWYD, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that patients have been dosed in the third cohort of a Phase 1 clinical
Read more →LRMRof Larimar s Amendment No. 1 to the Current Report on Form 8-K filed on
MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS On May 28, 2020, Larimar Therapeutics, Inc., formerly known as Zafgen, Inc. (the Company or Larimar ), completed its business combination with Chondrial Therapeutics, Inc., a Delaware corpora
Read more →LRMRChondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics - Shares of combined company to commence trading on Nasdaq Global Market under the symbol LRMR on May 29, 2020 $80 million in private placement financing with biotechnology focused in
Read more →LRMRLarimar Therapeutics to Present at Jefferies Virtual Healthcare Conference
BALA CYNWYD, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will
Read more →LRMRZafgen Reports Fourth Quarter and Full Year 2019 Financial Results Zafgen and Chondrial Therapeutics previously announced a definitive merger agreement Merger creates clinical-stage company focused on the development of
Zafgen Reports Fourth Quarter and Full Year 2019 Financial Results Zafgen and Chondrial Therapeutics previously announced a definitive merger agreement Merger creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Tra
Read more →LRMRZafgen and Chondrial Therapeutics Planned Definitive Merger February 2020 Forward Looking Statements Additional Information about the Proposed Merger and Where to Find It This communication relates to the proposed merger
February 2020Exhibit 99.1 Zafgen and Chondrial Therapeutics Planned Definitive Merger February 2020 Forward Looking Statements Additional Information about the Proposed Merger and Where to Find It This communication relates to the proposed merger transaction involving Zafgen, I
Read more →LRMRForward Looking Statements Additional Information about the Proposed Merger and Where to Find It This communication relates to the proposed merger transaction involving Zafgen, Inc. ("Zafgen") and Chondrial Therapeutics,
Zafgen and Chondrial Therapeutics Planned Definitive Merger January 2020 Exhibit 99.1 Forward Looking Statements Additional Information about the Proposed Merger and Where to Find It This communication relates to the proposed merger transaction involving Zafgen, Inc. ("Zafgen"
Read more →LRMRZafgen and Chondrial Therapeutics Announce Definitive Merger Agreement Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Chondrial Therapeutics lead asset,
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Chondrial Therapeutics lead asset, CTI-1601, currently being evaluated in Phase 1 clinical
Read more →LRMRZafgen Reports Third Quarter 2019 Financial Results Evaluation of strategic alternatives ongoing Boston
Zafgen Reports Third Quarter 2019 Financial Results Evaluation of strategic alternatives ongoing Boston, November 6, 2019 Zafgen, Inc. (Nasdaq:ZFGN) today reported its third quarter 2019 financial results. In September 2019, Zafgen announced plans to explore strategic options
Read more →LRMRZafgen Reports Second Quarter 2019 Operating and Financial Results Agreement reached with U.S. FDA on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety ma
Zafgen Reports Second Quarter 2019 Operating and Financial Results Agreement reached with U.S. FDA on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study expected by the
Read more →LRMRZafgen Announces Regulatory Update on ZGN-1061 Received FDA Type A meeting minutes related to previously announced clinical hold FDA acknowledged newly developed in vitro assays of human plasma coagulation and tissue fac
Zafgen Announces Regulatory Update on ZGN-1061 Received FDA Type A meeting minutes related to previously announced clinical hold FDA acknowledged newly developed in vitro assays of human plasma coagulation and tissue factor expression qualitatively differentiate ZGN-1061 Comp
Read more →LRMRZafgen Reports First Quarter 2019 Operating and Financial Results Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Company is currently in the formal regulatory process related
Zafgen Reports First Quarter 2019 Operating and Financial Results Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Company is currently in the formal regulatory process related to the clinical hold for ZGN-1061; Update still anticipat
Read more →LRMRZafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOSTON
Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOSTON, April 4, 2019 (GLOBE NEWSWIRE) Zafgen, Inc. (Nasdaq:ZFGN) (the Company ) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel
Read more →LRMRZafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 U
Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Updates on progress preparing for FDA Type A meeting for Z
Read more →LRMRZafgen Announces Positive Results for Second Cohort of Phase 2 Clinical Trial of ZGN-1061 Data for the 1.8 mg dose demonstrated meaningfully greater efficacy than the 0.9 mg dose Cohort 2 data showed statistically and cl
Zafgen Announces Positive Results for Second Cohort of Phase 2 Clinical Trial of ZGN-1061 Data for the 1.8 mg dose demonstrated meaningfully greater efficacy than the 0.9 mg dose Cohort 2 data showed statistically and clinically significant 1.1% reduction of A1C at the 1.8 mg
Read more →LRMRZafgen Provides Update on Investigational New Drug Application for ZGN-1061 Boston, Mass.
Zafgen Provides Update on Investigational New Drug Application for Boston, Mass., November 26, 2018 Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affe
Read more →LRMRZafgen Reports Third Quarter 2018 Operating and Financial Results ZGN-1061 1.8 mg cohort for the Phase 2 proof-of-concept trial now fully enrolled; on track for topline results early 2019 ZGN-1258 nonclinical safety and
Zafgen Reports Third Quarter 2018 Operating and Financial Results ZGN-1061 1.8 mg cohort for the Phase 2 proof-of-concept trial now fully enrolled; on track for topline results early 2019 ZGN-1258 nonclinical safety and efficacy data sets presented at Foundation for Prader-Wil
Read more →LRMRZafgen Reports Second Quarter 2018 Operating and Financial Results Phase 1 clinical trial for ZGN-1258 for Prader-Willi syndrome (PWS) expected to begin in the fourth quarter 2018 Multiple ZGN-1258 nonclinical studies ac
Zafgen Reports Second Quarter 2018 Operating and Financial Results Phase 1 clinical trial for ZGN-1258 for Prader-Willi syndrome (PWS) expected to begin in the fourth Multiple ZGN-1258 nonclinical studies accepted for presentation at upcoming Foundation for Prader-Willi Resear
Read more →LRMRZafgen Announces Departure of President and Chief Scientific Officer Dr. Thomas Hughes
Zafgen Announces Departure of President and Chief Scientific Officer Dr. Thomas Hughes BOSTON, Mass., August 2, 2018 Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a
Read more →LRMRZafgen Announces Proposed Offering of Common Stock
Zafgen Announces Proposed Offering of Common Stock BOSTON, Mass., June 27, 2018 Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic disea
Read more →LRMRZafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes Trial met all primary objectives, demonstrated efficacy and safety and establishe
Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes Trial met all primary objectives, demonstrated efficacy and safety and established minimally effective dose of 0.9 mg for ZGN-1061 Patient
Read more →LRMRZafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors Zafgen, Inc. also announces the retirements of Dr. Bruce Booth and Ms. Frances Heller from its Board of Dire
Zafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board Zafgen, Inc. also announces the retirements of Dr. Bruce Booth and Ms. Frances Heller from its Board of BOSTON, Mass., June 7, 2018 Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage b
Read more →LRMRZafgen, Inc. Expands Executive Leadership Team with Appointment of Brian McVeigh as Chief Business Officer
Zafgen, Inc. Expands Executive Leadership Team with Appointment of Brian McVeigh as Chief Business Officer BOSTON, Mass., May 30, 2018 Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help pati
Read more →LRMRZafgen Reports First Quarter 2018 Operating and Financial Results Multiple ZGN-1061 abstracts accepted for presentation at upcoming American Diabetes Association (ADA) Scientific Sessions ZGN-1061 Phase 1 SAD / MAD data
Zafgen Reports First Quarter 2018 Operating and Financial Results Multiple ZGN-1061 abstracts accepted for presentation at upcoming American Diabetes Association (ADA) Scientific Sessions ZGN-1061 Phase 1 SAD / MAD data published in Diabetes, Obesity Boston, Mass., May 8, 201
Read more →LRMRZafgen Reports Fourth Quarter and Full Year 2017 Financial Results; Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes ZGN-1061 interim data suggest comp
Zafgen Reports Fourth Quarter and Full Year 2017 Financial Results; Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes ZGN-1061 interim data suggest compound is safe and well-tolerated; no safety signals and pla
Read more →LRMRZafgen Reports Strong Clinical Progress and Updates Outlook for 2018 ZGN-1061 Phase 2 trial fully enrolled with type 2 diabetes patients; topline data expected mid-year Company returning to rare disorders with ZGN-1258;
Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018 ZGN-1061 Phase 2 trial fully enrolled with type 2 diabetes patients; topline data expected mid-year Company returning to rare disorders with ZGN-1258; Prader-Willi syndrome expected as first indication Incre
Read more →LRMRZafgen Reports Third Quarter 2017 Financial Results - Initiated Phase 2 Clinical Trial for Second Generation MetAP2 Inhibitor ZGN-1061 - - Expanded Executive Leadership Team - - Ended Quarter with Cash, Cash Equivalents
Zafgen Reports Third Quarter 2017 Financial Results - Initiated Phase 2 Clinical Trial for Second Generation MetAP2 Inhibitor ZGN-1061 - - Expanded Executive Leadership Team - - Ended Quarter with Cash, Cash Equivalents and Marketable Securities of $93.2 Million - BOSTON, Nov
Read more →LRMRZafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer BOSTON
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer BOSTON October 10, 2017 Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company dedicated to significantly improving th
Read more →LRMRZafgen Reports Second Quarter 2017 Financial Results -ZGN-1061 Phase 1 Data Support Continued Development for Obese Patients with Type 2 Diabetes- -Company to Initiate Phase 2 Clinical Trial in Third Quarter of This Year
Zafgen Reports Second Quarter 2017 Financial Results -ZGN-1061 Phase 1 Data Support Continued Development for Obese Patients with Type 2 Diabetes- -Company to Initiate Phase 2 Clinical Trial in Third Quarter of This Year- -Ends Quarter with Cash, Cash Equivalents and Marketabl
Read more →LRMRZafgen Reports First Quarter 2017 Financial Results -ZGN-1061 Phase 1 Data Support Continued Development; On Track to Initiate Phase 2 Clinical Trial in Patients with Type 2 Diabetes in Second Half of This Year- BOSTON
Zafgen Reports First Quarter 2017 Financial Results -ZGN-1061 Phase 1 Data Support Continued Development; On Track to Initiate Phase 2 Clinical Trial in Patients with Type 2 Diabetes in Second Half of This Year- BOSTON, May 9, 2017 Zafgen, Inc. (Nasdaq:ZFGN), today announced i
Read more →LRMRZafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor - Clinical Trial Shows Weight Loss Trends of Up to One Pound Per Week and an Early Favorable Safety and Tolerability Profi
Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor - Clinical Trial Shows Weight Loss Trends of Up to One Pound Per Week and an Early Favorable Safety and Tolerability Profile - - Improvements in Metabolic Parameters and Trends for
Read more →LRMRZafgen Reports Fourth Quarter and Full Year 2016 Financial Results -On Track to Complete Dosing of Phase 1 Clinical Trial for ZGN-1061 by the End of the First Quarter of 2017- BOSTON
Zafgen Reports Fourth Quarter and Full Year 2016 Financial Results -On Track to Complete Dosing of Phase 1 Clinical Trial for ZGN-1061 by the End of the First Quarter of 2017- BOSTON, March 9, 2017 Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significant
Read more →LRMRZafgen Reports Third Quarter 2016 Financial Results -Advancing Phase 1 Clinical Trial of ZGN-1061; Top-Line Results Expected First Quarter 2017- BOSTON
Zafgen Reports Third Quarter 2016 Financial Results -Advancing Phase 1 Clinical Trial of ZGN-1061; Top-Line Results Expected First Quarter 2017- BOSTON, November 9, 2016 Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and
Read more →LRMRZafgen Reports Second Quarter 2016 Financial Results BOSTON
Zafgen Reports Second Quarter 2016 Financial Results BOSTON, August 4, 2016 Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced it
Read more →LRMRZafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061 -ZGN-1061 in Phase I Development for Severe and Complicated Obesity Indications- - Suspending Development of Beloran
Zafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061 -ZGN-1061 in Phase I Development for Severe and Complicated Obesity Indications- - Suspending Development of Beloranib; Implementing Strategic Restructuring to Align Operatio
Read more →LRMRZafgen Reports First Quarter 2016 Financial Results - Conference call scheduled for 4:30 PM Eastern Time- BOSTON
Zafgen Reports First Quarter 2016 Financial Results - Conference call scheduled for 4:30 PM Eastern Time- BOSTON, May 10, 2016 Zafgen (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and c
Read more →LRMRZafgen Reports Fourth Quarter and Full Year 2015 Financial Results - Conference call scheduled for 4:30 PM Eastern Time - BOSTON
Zafgen Reports Fourth Quarter and Full Year 2015 Financial Results - Conference call scheduled for 4:30 PM Eastern Time - BOSTON, March 9, 2016 Zafgen (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected
Read more →LRMRZafgen Adds Thomas O. Daniel, M.D. to its Board of Directors BOSTON
Zafgen Adds Thomas O. Daniel, M.D. to its Board of Directors BOSTON March 8, 2016 Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announ
Read more →LRMRZafgen s Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint - Beloranib demonstrates statistically and clinically significant improvements in body weight and g
Zafgen s Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint - Beloranib demonstrates statistically and clinically significant improvements in body weight and glycemic control over six months of randomized treatment
Read more →LRMRZafgen s Pivotal Phase 3 Trial of Beloranib in Prader-Willi Syndrome Achieves Co-Primary Efficacy Endpoints - bestPWS Study is the first Phase 3 pivotal trial to show significant weight-loss and improve hyperphagia-relat
Zafgen s Pivotal Phase 3 Trial of Beloranib in Prader-Willi Syndrome Achieves Co-Primary Efficacy Endpoints - bestPWS Study is the first Phase 3 pivotal trial to show significant weight-loss and improve hyperphagia-related behaviors in PWS patients- -Statistically significant
Read more →LRMRZafgen Provides Clinical Update on Beloranib BOSTON
Zafgen Provides Clinical Update on Beloranib BOSTON Dec. 2, 2015 Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today provided an update on t
Read more →LRMRZafgen Announces Beloranib IND Placed on Complete Clinical Hold BOSTON
Zafgen Announces Beloranib IND Placed on Complete Clinical Hold BOSTON Dec. 2, 2015 Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today rece
Read more →LRMRZafgen Announces Third Quarter 2015 Financial Results Company to Host Conference Call at 4:30 PM Eastern Time to Review Progress with Beloranib Program Ends Quarter with Cash, Cash Equivalents and Marketable Securities o
Zafgen Announces Third Quarter 2015 Financial Results Company to Host Conference Call at 4:30 PM Eastern Time to Review Progress with Beloranib Program Ends Quarter with Cash, Cash Equivalents and Marketable Securities of $204 Million; Increases Year-End Cash Guidance to Great
Read more →LRMRZafgen Announces Beloranib Program Update -Company Elects to Proceed with Data Analysis for the Pivotal Phase 3 Study in Prader-Willi Syndrome and the Phase 2b in Severe Obesity Complicated by Type 2 Diabetes- -Open Labe
Zafgen Announces Beloranib Program Update -Company Elects to Proceed with Data Analysis for the Pivotal Phase 3 Study in Prader-Willi Syndrome and the Phase 2b in Severe Obesity Complicated by Type 2 Diabetes- -Open Label Extension Portion of Phase 3 Prader-Willi Syndrome Stud
Read more →LRMRZafgen Announces Partial Clinical Hold Affecting Beloranib Trials Investor Conference Call Today, October 1 6 th, at 8:30 a.m.
Zafgen Announces Partial Clinical Hold Affecting Beloranib Trials Investor Conference Call Today, October 16th, at 8:30 a.m. E.T. BOSTON Oct. 16, 2015 Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of pati
Read more →LRMRZafgen Announces Transition of Board of Directors -Adds Significant Industry Leadership Experience- BOSTON
Zafgen Announces Transition of Board of Directors -Adds Significant Industry Leadership Experience- BOSTON September 28, 2015 Zafgen, Inc. (Nasdaq: ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity
Read more →LRMRZafgen, Inc. Patricia Allen Chief Financial Officer 617-648-9792 FTI Consulting Kimberly Ha Investor Relations (212) 850-5612 Kimberly.Ha@fticonsulting.com Shauna Elkin Media Relations (212) 850-5613 Shauna.Elk
Chief Financial Officer Kimberly.Ha@fticonsulting.com Shauna.Elkin@fticonsulting.com Zafgen Reports Second Quarter 2015 Financial Results Quarter Highlighted by Completion of Enrollment in bestPWS Phase 3 Clinical Trial Six Month Data on Track for Release in Early Q1 2016 O
Read more →LRMRMedia & Investor Relations Contact: Shauna Elkin (212) 850-5613 Shauna.Elkin@fticonsulting.com Zafgen Announces Positive Results From Phase 2 Clinical Trial of Beloranib in Hypothalamic Injury Associated Obesity BOSTON
Media & Investor Relations Contact: Shauna.Elkin@fticonsulting.com Zafgen Announces Positive Results From Phase 2 Clinical Trial of Beloranib in Hypothalamic Injury Associated Obesity BOSTON, Jan. 7, 2015 Zafgen (Nasdaq:ZFGN), a biopharmaceutical company dedicated to signific
Read more →LRMRZafgen, Inc. Patricia Allen Chief Financial Officer 617-648-9792 FTI Consulting Brian Ritchie Investor Relations (212) 850-5683 Brian.Ritchie@fticonsulting.com Shauna Elkin Media Relations (212) 850-5613 Shauna
Chief Financial Officer Brian.Ritchie@fticonsulting.com Shauna.Elkin@fticonsulting.com Zafgen Reports Third Quarter 2014 Financial Results Quarter Highlighted by Significant Progress in Advancing Beloranib Clinical Development Program Company Expects to Report Data from Thre
Read more →LRMRZafgen, Inc. Patricia Allen Chief Financial Officer 617-648-9792 Brian Ritchie (212) 850-5683 Brian.Ritchie@fticonsulting.com Zafgen Reports Second Quarter 2014 Financial Results Quarter Highlighted by Successf
Chief Financial Officer Brian.Ritchie@fticonsulting.com Zafgen Reports Second Quarter 2014 Financial Results Quarter Highlighted by Successful Completion of Initial Public Offering and Receipt of $102.7 Million in Net Proceeds Progressed Clinical Pipeline with Start of ZAF-22
Read more →Competitive Position
How LRMR ranks across every disease it competes inCompetitive Position is a premium feature
See how LRMR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial